Kirkland & Ellis’s recently hired Boston team has scored a key role advising Avidity Biosciences on its $12bn acquisition by Swiss pharma giant Novartis.
The team, which joined earlier this year from Skadden, is advising San Diego-based RNA therapeutics developerAvidity opposite Covington & Burling for Novartis.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
